Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-20
2009-06-02
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07541371
ABSTRACT:
According to the present invention, there is provided a method for treating a motor neuron disease, comprising the step of administering a therapeutically effective amount of a compound having serotonin receptor antagonist activity or its pharmacologically acceptable salt or their solvate optionally together with a pharmaceutically acceptable carrier to a mammal for which the treatment of said disease is indicated.
REFERENCES:
patent: 6340759 (2002-01-01), Ueno et al.
patent: 2005/0256103 (2005-11-01), Suzuki et al.
patent: 2007/0219179 (2007-09-01), Suzuki et al.
patent: 2005-225845 (2005-08-01), None
patent: 98/43956 (1998-10-01), None
patent: 99/18077 (1999-04-01), None
patent: 02/078643 (2002-10-01), None
patent: 2005/108389 (2005-11-01), None
CLG Lin, et al., “Abberant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis”,Neuron, vol. 20, pp. 589-602, Mar. 1998.
T Meyer, et al., “The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals”,J. Neur. Sci., vol. 170, pp. 45-50, 1999.
HX Deng, et al., “Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase”,Science, vol. 261, pp. 1047-1051, Aug. 1993.
DR Rosen, et al., “Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis”,Nature, vol. 362, pp. 59-62, Mar. 4, 1993.
M Nagai, et al., “Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease”,J. Neurosci., vol. 21, No. 23, pp. 9246-9254, Dec. 1, 2001.
ME Gurney, et al., “Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation”,Science, vol. 264, pp. 1772-1775, Jun. 17, 1994.
LP Rowland, et al., “Amyotrophic lateral sclerosis”,N. Engl. J. Med., vol. 344, No. 22, pp. 1688-1700, May 31, 2001.
JP Julien, et al., “Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded”,Cell, vol. 104, pp. 581-591, Feb. 23, 2001.
Y Kawahara, et al., “RNA editing and death of motor neurons”,Nature, vol. 427, pp. 801, Feb. 26, 2004.
SA Lipton, et al., “Sporadic ALS: blame it on the editor”,Nature Medicine, vol. 10, No. 4, pp. 347, Apr. 2004.
DW Cleveland and JD Rothstein, “From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS”,Nature Reviews: Neuroscience, vol. 2, pp. 806-819, Nov. 2001.
HJL Fryer, et al., “Excitotoxic death of a subset of embryonic rat motor neurons in vitro”,J. Neurochem., vol. 72, No. 2, pp. 500-513, 1999.
G Bensimon, et al., “A controlled trial riluzole in amyotrophic lateral sclerosis”,New England Journal of Medicine, vol. 330, No. 9, pp. 585-591, Mar. 3, 1994.
L Lacomblez, et al., “Dose-ranging study of riluzole in amyotrophic lateral sclerosis”,Lancet, vol. 347, pp. 1425-1431, May 25, 1996.
Y Arakawa, et al., “Survival effect of ciliary neurotrophic factor (CNTF) on chick embryonic motoneurons in culture: comparison with other neurotrophic factors and cytokines”,J. Neurosci., vol. 10, No. 11, pp. 3507-3515, Nov. 1990.
DN Ishii and DJ Marsh, “On the therapeutic potential for insulin-like growth factor use in motor neuron disease”,Experimental Neurology, vol. 124, pp. 96-99, 1993.
ME Lewis, et al., “Insulin-like growth factor-I: Potential for treatment of motor neuronal disorders”,Experimental Neurology, vol. 124, pp. 73-88, 1993.
M Sendtner, et al., “Actions of CNTF and neurotrophins on degenerating motoneurons: preclinical studies and clinical implications”,Journal of the Neurological Sciences, vol. 124 (Suppl.), pp. 77-83, 1994.
RM Lindsay, “Therapeutic potential of the neurotrophins and neurotrophin-CNTF combinations in peripheral neuropathies and motor neuron diseases”, Ciba Found Symp., vol. 196, pp. 39-53, 1996.
E Storkebaum, et al., “Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS”,Nature Neuroscience, vol. 8, No. 1, pp. 85-92, Jan. 2005.
H Thoenen and Michael Sendtner, “Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches”,Nature Neuroscience supplement, vol. 5, pp. 1046-1050, Nov. 2002.
Hans Hultborn and Ole Kiehn, “Neuromodulation of vertebrate motor neuron membrane properties”,Current Opinion in Neurobiology, vol. 2, pp. 770-775, 1992.
JF Perrier and J Hounsgaard, “5-HT2receptors promote plateau potentials in turtle spinal motoneurons by facilitating an L-type calcium current”,J. Neurophysiol., vol. 89, pp. 954-959, 2003.
DV Volgin, et al., “Postnatal development of serotonin 1B, 2A and 2C receptors in brainstem motoneurons”,European Journal of Neuroscience, vol. 17, pp. 1179-1188, 2003.
JL Ridet, et al., “Direct immunocytochemical localization of 5-hydroxytryptamine receptors in the adult rat spinal cord: a light and electron microscopic study using an anti-idiotypic antiserum”,Journal of Neuroscience Research, vol. 38, pp. 109-121, 1994.
T Hayashi, et al., “Developmental changes in serotonergic receptor-mediated modulation of embryonic chick motoneurons in vitro”,Developmental Brain Research, vol. 102, pp. 21-33, 1997.
MY Wang and NJ Dun, “5-hydroxytryptamine responses in neonate rat motoneurones in vitro”,Journal of Physiology, vol. 430, pp. 87-103, 1990.
EM Talley, et al., “Postnatal development of serotonergic innervation, 5-HT1Areceptor expression, and 5-HT responses in rat motoneurons”,Journal of Neuroscience, vol. 17, No. 11, pp. 4473-4485, Jun. 1, 1997.
M Antri, et al., “Locomotor recovery in the chronic spinal rat: effects of long-term treatment with a 5-HT2agonist”,European Journal of Neuroscience, vol. 16, pp. 467-476, 2002.
O Bertel, et al., “Amyotrophic lateral sclerosis: changes of noradrenergic and serotonergic transmitter systems in the spinal cord”,Brain Research, vol. 566, pp. 54-60, 1991.
BJ Turner, et al., “The serotonin precursor 5-hydroxytryptophan delays neuromuscular disease in murine familial amyotrophic lateral sclerosis”,ALS and other motor neuron disorders, vol. 4, pp. 171-176, 2003.
Y Iwasaki, et al., “SR57746A: a survival factor for motor neurons in vivo”,Journal of the Neurological Sciences, vol. 160 (Suppl. 1), S92-S96, 1998.
C Labie, et al., “Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex”,British Journal of Pharmacology, vol. 127, pp. 139-144, 1999.
V. Meininger, et al., “Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials”,ALS and other motor neuron disorders, vol. 5, pp. 107-117, 2004.
L Lacomblez, et al., “Xaliproden in amyotrophic lateral sclerosis: early clinical trials”,ALS and other motor neuron disorders, vol. 5, pp. 99-106, 2004.
MW Jann, “Buspirone: an update on a unique anxiolytic agent”,Pharmacotherapy, vol. 8, No. 2, pp. 100-116, 1988.
BJ Turner, et al., “Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice”,Journal of Neuroscience Research, vol. 74, pp. 605-613, 2003.
K Ohsugi, et al., “Lack of change in indoleamine metabolism in spinal cord of patients with amyotrophic lateral sclerosis”,Neuroscience Letters, vol. 79, pp. 351-354, 1987.
M Damiano, et al., “Neural mitochondrial Ca2+capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice”,Journal of Neurochemistry, vol. 96, pp. 1349-1361, 2006.
E Sharifullina and A Nistri, “Glutamate uptake block trigg
Arakawa Yoshihiro
Miyazaki Makoto
Eisai R&D Management Co., Ltd.
Henley, III Raymond J
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Method for treating a motor neuron disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating a motor neuron disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating a motor neuron disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4117919